Epizyme Inc (EPZM) 22.55 $EPZM
POC study for EPZ-5676 in Pediatric MLL-r patients initiated by Epizyme
M2 - Wed May 07, 10:08AM CDT
Biopharmaceutical company Epizyme Inc (NASDAQ:EPZM), announced on Wednesday the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene (MLL-r).
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014: Includes 126 Company breakdowns
M2 - Wed May 07, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v5fq8h/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - 4SC AG - AB Science - AIMM Therapeutics B.V. - AROG Pharmaceuticals LLC - Boehringer Ingelheim GmbH - Coronado Biosciences, Inc. - Critical Outcome Technologies Inc. - CureTech Ltd. - Cyclacel Pharmaceuticals Inc. - ERYtech Pharma - Egenix, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - EntreMed, Inc. - EpiZyme, Inc. - Esperance Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - Genentech, Inc. - medac GmbH For more information visit http://www.researchandmarkets.com/research/v5...myelocytic
Epizyme, Inc. to Report First Quarter Financial Results and Provide Corporate Update on May 13, 2014
PR Newswire - Wed May 07, 8:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Tuesday, May 13, 2014, at 4:30 p.m. ET to report first quarter 2014 financial results and provide a corporate update.
Epizyme Initiates Pediatric MLL-r Proof-of-Concept Study for EPZ-5676
PR Newswire - Wed May 07, 6:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene (MLL-r). This Phase 1b study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of 3 months and 18 years and to provide a preliminary assessment of efficacy. Including this study, Epizyme now has ongoing assessments of proof-of-concept (POC) in three genetically defined cancer patient groups in the EPZ-5676 clinical program (MLL-r adults, MLL-PTD, and MLL-r pediatrics) with expected data disclosures in the second half of 2014.
Epizyme, Inc. to Present at Upcoming Conferences in May
PR Newswire - Thu May 01, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in May:
Epizyme Nominates Dr. Andrew R. Allen For Election to Board of Directors
PR Newswire - Wed Apr 30, 4:24PM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew R. Allen, M.D., Ph.D., co-founder and Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer of Clovis Oncology, Inc., has been nominated for election to the company's board of directors. The election of directors will take place at the company's annual meeting, scheduled for June 9, 2014.
'Mad Money' Lightning Round: Stick With Baidu
at The Street - Sat Apr 26, 5:00AM CDT
Cramer thinks Genomic Health can go lower, doesn't like Molycorp but likes SandRidge Energy and its CEO.
Epizyme Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treatment for Cancers with EZH2 Inhibitors
PR Newswire - Thu Apr 24, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted a notice of allowance for U.S. Patent Application No. 13/722,807 with claims that cover methods of treating cancer with EZH2 inhibitors. The patent, entitled "Aryl-or Heteroaryl-Substituted Benzene Compounds," will expire in 2033.
Epizyme Up on Milestone Payment from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 6:10PM CDT
Shares of Epizyme (EPZM) were up 8.3% after the company announced the achievement of one of the HMT targets.
Why Epizyme Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 11:40AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Epizyme , a clinical-stage...
Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments
PR Newswire - Tue Apr 22, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate milestone for the third of the three histone methyltransferase (HMT) targets in the company's collaboration with GSK and is receiving $4 million in milestone and license payments.
Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation
PR Newswire - Tue Apr 08, 6:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients carrying EZH2 oncogenic mutations as candidates for treatment with EZH2 inhibitors. EZH2 is a histone methyltransferase (HMT) that can become oncogenic due to genetic alterations and cause non-Hodgkin lymphoma and solid tumors. The patent, entitled "Inhibitors of Human EZH2 and Methods of Use Thereof," expires in 2033.
Epizyme (EPZM): Moving Average Crossover Spotted - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 9:02AM CDT
Epizyme (EPZM): Moving Average Crossover Spotted
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
Epizyme, Inc. to Present at 34th Annual Cowen and Company Health Care Conference on March 3, 2014
PR Newswire - Fri Feb 28, 7:30AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation at the Cowen and Company 34th Annual Health Care Conference.
Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance
PR Newswire - Thu Feb 27, 3:00PM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced 2013 operating and financial results and provided 2014 guidance.
Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone
PR Newswire - Thu Feb 27, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate selection milestone for one of the histone methyltransferase (HMT) targets in the company's collaboration with GSK. This achievement triggers a milestone payment of $2 million and follows the announcement in January 2014 of the achievement of a development candidate milestone for another of the HMT targets in the collaboration, which earned Epizyme a $4 million milestone payment.
Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma
PR Newswire - Fri Feb 21, 7:11AM CST
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data from preclinical studies of the company's clinical candidate EPZ-6438 (E7438), a potent and selective small-molecule inhibitor of EZH2, a histone methyltransferase (HMT). Oncogenic mutations in EZH2 occur in a subset of patients with non-Hodgkin lymphoma (NHL), implicating EZH2 as a therapeutic target in these patients. This research, published online today and in the April issue of the journal Molecular Cancer Therapeutics, provides a preclinical description of EPZ-6438, which Epizyme is developing in partnership with Eisai for the treatment of EZH2 mutant-bearing NHL. The paper expands on data reported by the same authors in a poster presentation at the December 2012 American Society of Hematology (ASH) annual meeting.
Epizyme, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:57PM CST
The following issues have been halted by IIROC:
Epizyme, Inc. to Report Fourth Quarter and Year-End 2013 Financial Results on February 27, 2014
PR Newswire - Wed Feb 19, 3:30PM CST
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, February 27, 2014, at 4:30 p.m. ET to report fourth quarter and year-end 2013 financial results.
POC study for EPZ-5676 in Pediatric MLL-r patients initiated by Epizyme
M2 - Wed May 07, 10:08AM CDT
Biopharmaceutical company Epizyme Inc (NASDAQ:EPZM), announced on Wednesday the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene (MLL-r).
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014: Includes 126 Company breakdowns
M2 - Wed May 07, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v5fq8h/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - 4SC AG - AB Science - AIMM Therapeutics B.V. - AROG Pharmaceuticals LLC - Boehringer Ingelheim GmbH - Coronado Biosciences, Inc. - Critical Outcome Technologies Inc. - CureTech Ltd. - Cyclacel Pharmaceuticals Inc. - ERYtech Pharma - Egenix, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - EntreMed, Inc. - EpiZyme, Inc. - Esperance Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - Genentech, Inc. - medac GmbH For more information visit http://www.researchandmarkets.com/research/v5...myelocytic
Epizyme, Inc. to Report First Quarter Financial Results and Provide Corporate Update on May 13, 2014
PR Newswire - Wed May 07, 8:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Tuesday, May 13, 2014, at 4:30 p.m. ET to report first quarter 2014 financial results and provide a corporate update.
Epizyme Initiates Pediatric MLL-r Proof-of-Concept Study for EPZ-5676
PR Newswire - Wed May 07, 6:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene (MLL-r). This Phase 1b study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of 3 months and 18 years and to provide a preliminary assessment of efficacy. Including this study, Epizyme now has ongoing assessments of proof-of-concept (POC) in three genetically defined cancer patient groups in the EPZ-5676 clinical program (MLL-r adults, MLL-PTD, and MLL-r pediatrics) with expected data disclosures in the second half of 2014.
Epizyme, Inc. to Present at Upcoming Conferences in May
PR Newswire - Thu May 01, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in the following conferences in May:
Epizyme Nominates Dr. Andrew R. Allen For Election to Board of Directors
PR Newswire - Wed Apr 30, 4:24PM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew R. Allen, M.D., Ph.D., co-founder and Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer of Clovis Oncology, Inc., has been nominated for election to the company's board of directors. The election of directors will take place at the company's annual meeting, scheduled for June 9, 2014.
'Mad Money' Lightning Round: Stick With Baidu
at The Street - Sat Apr 26, 5:00AM CDT
Cramer thinks Genomic Health can go lower, doesn't like Molycorp but likes SandRidge Energy and its CEO.
Epizyme Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treatment for Cancers with EZH2 Inhibitors
PR Newswire - Thu Apr 24, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted a notice of allowance for U.S. Patent Application No. 13/722,807 with claims that cover methods of treating cancer with EZH2 inhibitors. The patent, entitled "Aryl-or Heteroaryl-Substituted Benzene Compounds," will expire in 2033.
Epizyme Up on Milestone Payment from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 6:10PM CDT
Shares of Epizyme (EPZM) were up 8.3% after the company announced the achievement of one of the HMT targets.
Why Epizyme Inc. Shares Rocketed Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 11:40AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Epizyme , a clinical-stage...
Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments
PR Newswire - Tue Apr 22, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate milestone for the third of the three histone methyltransferase (HMT) targets in the company's collaboration with GSK and is receiving $4 million in milestone and license payments.
Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation
PR Newswire - Tue Apr 08, 6:30AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients carrying EZH2 oncogenic mutations as candidates for treatment with EZH2 inhibitors. EZH2 is a histone methyltransferase (HMT) that can become oncogenic due to genetic alterations and cause non-Hodgkin lymphoma and solid tumors. The patent, entitled "Inhibitors of Human EZH2 and Methods of Use Thereof," expires in 2033.
Epizyme (EPZM): Moving Average Crossover Spotted - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 9:02AM CDT
Epizyme (EPZM): Moving Average Crossover Spotted
What You Ought To Know About Celgene's Deal-Making Magic
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 05, 5:30PM CST
Celgene , the biotech giant best known for its $4 billion a year myeloma drug Revlimid, has been among the most active in making deals with young biotech companies. In January, Celgene made its latest deal, handing over $50 million to cozy up to...
Epizyme, Inc. to Present at 34th Annual Cowen and Company Health Care Conference on March 3, 2014
PR Newswire - Fri Feb 28, 7:30AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation at the Cowen and Company 34th Annual Health Care Conference.
Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance
PR Newswire - Thu Feb 27, 3:00PM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced 2013 operating and financial results and provided 2014 guidance.
Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone
PR Newswire - Thu Feb 27, 7:00AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate selection milestone for one of the histone methyltransferase (HMT) targets in the company's collaboration with GSK. This achievement triggers a milestone payment of $2 million and follows the announcement in January 2014 of the achievement of a development candidate milestone for another of the HMT targets in the collaboration, which earned Epizyme a $4 million milestone payment.
Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma
PR Newswire - Fri Feb 21, 7:11AM CST
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data from preclinical studies of the company's clinical candidate EPZ-6438 (E7438), a potent and selective small-molecule inhibitor of EZH2, a histone methyltransferase (HMT). Oncogenic mutations in EZH2 occur in a subset of patients with non-Hodgkin lymphoma (NHL), implicating EZH2 as a therapeutic target in these patients. This research, published online today and in the April issue of the journal Molecular Cancer Therapeutics, provides a preclinical description of EPZ-6438, which Epizyme is developing in partnership with Eisai for the treatment of EZH2 mutant-bearing NHL. The paper expands on data reported by the same authors in a poster presentation at the December 2012 American Society of Hematology (ASH) annual meeting.
Epizyme, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:57PM CST
The following issues have been halted by IIROC:
Epizyme, Inc. to Report Fourth Quarter and Year-End 2013 Financial Results on February 27, 2014
PR Newswire - Wed Feb 19, 3:30PM CST
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, February 27, 2014, at 4:30 p.m. ET to report fourth quarter and year-end 2013 financial results.
